Trastuzumab-related cardiac events in the treatment of early breast cancer

Trastuzumab is considered a cornerstone in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. Cardiac toxicity is an important side effect of treatment and can limit the use of this drug known to act synergistically with cardiotoxicity from anthracyclines. A ret...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2013-11, Vol.142 (1), p.1-7
Hauptverfasser:	Fried, Georgeta, Regev, Tslil, Moskovitz, Mor
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Adult Aged Analysis Anthracyclines Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast cancer Breast Neoplasms - complications Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Cancer research Cancer therapies Cardiovascular system Care and treatment Chemotherapy, Adjuvant Drug therapy Epidermal growth factor Female Gynecology. Andrology. Obstetrics Health aspects Heart Diseases - chemically induced Humans Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoadjuvant Therapy Neoplasm Staging Oncology Retrospective Studies Review Risk Factors Side effects Toxicity Trastuzumab Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!